Neuland Laboratories Ltd — earnings calls

Neuland Laboratories reported total income of INR650.1 crores for Q1FY27, up 16.3% year-on-year, with EBITDA margin at 35.5% and PAT of INR147.4 crores compared to INR13.7 crores a year earlier. Management attributed growth primarily to commercial CMS projects and a favorable customer mix, while working capital days improved from 137 to 84. The company also discussed a strategic collaboration with Gland Pharma for sterile API manufacturing and progress on its peptide manufacturing facility, which is expected to be commissioned the following month.

Neuland Laboratories reported Q4 FY26 total income of Rs 788.7 crore, up 134.9% year-on-year, driven largely by commercial CMS projects and favorable exchange rates. EBITDA margin for the quarter stood at 40.5%, which management described as exceptional and reflective of record revenue and the uneven nature of the business rather than a sustainable run rate. For the full year, revenue grew 37.1% to Rs 2,053.1 crore with EBITDA margin at 29.4%, while working capital days rose to 137 in Q4FY26 from 107 a year earlier.